United States Small Nucleic Acid-Based Drug Market was valued at USD 2.1 Billion in 2022 and is projected to reach USD 5.5 Billion by 2030, growing at a CAGR of 13.4% from 2024 to 2030.
The U.S. small nucleic acid-based drug market is seeing significant growth, driven by breakthroughs in genetic medicine and advancements in biotechnology. Small nucleic acids, such as oligonucleotides and RNA-based drugs, offer targeted therapies that can modify gene expression and address previously untreatable conditions. The market for these drugs is expected to expand rapidly, fueled by an increasing understanding of the human genome and the growing demand for personalized treatments.
In recent years, small nucleic acid-based drugs, especially RNA therapies like mRNA vaccines and gene-editing technologies, have transformed the medical landscape. The U.S. market has seen a surge in investment, with pharmaceutical companies developing novel drugs targeting a wide range of diseases, from genetic disorders to cancer. The adoption of mRNA-based therapies in particular has been accelerated by the success of COVID-19 vaccines, setting the stage for further innovation.
One key factor contributing to this market growth is the expanding pipeline of drug candidates. Currently, there are over 40 RNA-based therapeutics in late-stage development, addressing conditions such as muscular dystrophy, cystic fibrosis, and various cancers. These therapies are being seen as the future of medicine due to their ability to provide more precise, efficient, and safer treatments compared to traditional small molecule drugs.
The market is also benefitting from the growing collaboration between biotech startups and established pharmaceutical giants. With companies such as Moderna, BioNTech, and Alnylam Pharmaceuticals leading the charge, small nucleic acid drugs are becoming an essential part of many treatment regimens. Additionally, advancements in delivery systems and technologies for RNA-based therapeutics are making it easier to ensure these drugs reach their intended targets with minimal side effects.
Moreover, the broader healthcare ecosystem is embracing the potential of small nucleic acid drugs. Public awareness, regulatory approvals, and increasing demand for more targeted therapies all contribute to the momentum behind this market. As new treatments reach the market, it is likely that small nucleic acid-based drugs will become even more integrated into modern healthcare systems.
With the U.S. market poised for growth, the future of small nucleic acid-based drugs is looking bright, offering hope for a wide array of diseases that were once considered beyond the reach of conventional medicine.
Get an In-Depth Research Analysis of the US Small Nucleic Acid-Based Drug Market Size And Forecast [2025-2032]
Biogen
Pfizer
Jazz
Sarepta Therapeutics
Alnylam
Novartis
Nippon Shinyaku
Swedish Orphan Biovitrum
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the US Small Nucleic Acid-Based Drug Market Size And Forecast [2025-2032]
Growing demand for below applications around the world has had a direct impact on the growth of the US Small Nucleic Acid-Based Drug Market
Antisense Oligonucleotides
Small Interfering RNAs (siRNAs)
MicroRNAs (miRNAs)
RNA Aptamers
Other Nucleic Acid-Based Drugs
Oncology
Cardiovascular Disorders
Neurological Disorders
Infectious Diseases
Genetic Disorders
Intravenous (IV)
Subcutaneous
Intradermal
Oral
Nasal
Pharmaceutical Companies
Biotechnology Firms
Research Institutions
Contract Research Organizations (CROs)
Hospitals and Clinics
Preclinical
Clinical Stage I
Clinical Stage II
Clinical Stage III
Commercialized
US (United States, US and Mexico)
Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
South America (Brazil, Argentina, Columbia, etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
For More Information or Query, Visit @ Small Nucleic Acid-Based Drug Market Research Analysis
1. Introduction of the US Small Nucleic Acid-Based Drug Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. US Small Nucleic Acid-Based Drug Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. US Small Nucleic Acid-Based Drug Market, By Type
6. US Small Nucleic Acid-Based Drug Market, By Application
7. US Small Nucleic Acid-Based Drug Market, By Geography
US
Europe
Asia Pacific
Rest of the World
8. US Small Nucleic Acid-Based Drug Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading US Research and Consulting firm servicing over 5000+ US clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.verifiedmarketreports.com/